Extrahepatic bile duct carcinoma
MONDO:0003090A carcinoma that arises from epithelial cells of the extrahepatic bile duct.
Also known as: carcinoma of extrahepatic bile duct, carcinoma of the extrahepatic bile duct, extrahepatic bile duct cancer, extrahepatic bile duct carcinoma
3329 clinical trials for this condition and its sub-types, 51 tagged with Extrahepatic bile duct carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Extrahepatic bile duct carcinoma
-
Extrahepatic bile duct adenocarcinoma 2 trials · 409 incl. sub-types
7 sub-types
- Adenocarcinoma of gallbladder and extrahepatic biliary tract 6 trials · 374 incl. sub-types Sub-types →
- Ampulla of vater adenocarcinoma 11 trials · 42 incl. sub-types Sub-types →
- Extrahepatic bile duct clear cell adenocarcinoma 0 trials Sub-types →
- Extrahepatic bile duct mucinous adenocarcinoma 0 trials Sub-types →
- Extrahepatic bile duct signet ring cell carcinoma 0 trials Sub-types →
- Extrahepatic bile duct small cell adenocarcinoma 0 trials
- Papillary extrahepatic bile duct adenocarcinoma 0 trials
-
Carcinoma of the ampulla of vater 29 trials · 65 incl. sub-types
3 sub-types
- Ampulla of vater adenocarcinoma 11 trials · 42 incl. sub-types Sub-types →
- Ampulla of vater small cell neuroendocrine carcinoma 0 trials
- Ampulla of vater squamous cell carcinoma 0 trials Sub-types →
-
Distal biliary tract carcinoma 32 trials
Most studied deeper sub-types
-
Experimental antibody takes on tough bile duct cancers
Disease control CompletedThis phase 2 trial tests an experimental drug called XmAb20717 in 27 adults with advanced biliary tract cancers (bile duct or gallbladder cancer) that worsened after standard chemotherapy. The drug is a bispecific antibody designed to activate the immune system against cancer by …
Phase 2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Sep 21, 2026 20:00 UTC
-
Immunotherapy combo shows promise for tough bile duct cancer
Disease control CompletedThis study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine/cisplatin) helps people with advanced bile duct or gallbladder cancer live longer. Over 1,000 participants received either the combination or chemo plus a placebo. The goal…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug cocktail shows promise against tough cancers
Disease control CompletedThis study tested a combination of two experimental drugs, AK112 and AK117, with or without chemotherapy, in 154 people with advanced solid tumors. The goal was to see if the combo could shrink tumors and control the disease. The trial has finished, and researchers are now lookin…
Phase 1/2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Triple chemo attack shows promise against tough bile duct cancers
Disease control CompletedThis phase III trial tested whether adding nab-paclitaxel to the standard two-drug chemo (gemcitabine and cisplatin) helps people with newly diagnosed, advanced biliary tract cancers live longer. Over 450 patients took part. The goal is to see if the three-drug combo improves ove…
Phase 3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Robot surgeons take on pancreatic cancer in major trial
Disease control CompletedThis study compared robotic-assisted pancreatic surgery to the standard open approach for people with pancreatic and related tumors. Researchers wanted to see if robotic surgery could help patients recover faster after the operation. A total of 268 patients took part across multi…
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug combo shows promise for Tough-to-Treat bile duct cancer
Disease control CompletedThis phase 2 trial tested a new chemotherapy combination (Nal-IRI with 5-FU and leucovorin) against a standard treatment (gemcitabine plus cisplatin) in 93 people with advanced biliary tract cancer that could not be removed by surgery. The study aimed to see which approach better…
Phase 2 • Sponsor: AIO-Studien-gGmbH • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New drug ZW25 shows promise for rare bile duct cancer
Disease control CompletedThis study tested a drug called ZW25 (zanidatamab) in 87 people with advanced or metastatic HER2-amplified biliary tract cancer that had worsened after standard chemotherapy. The goal was to see if the drug could shrink tumors and how long that effect lasted. The trial is now com…
Phase 2 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 26, 2026 17:24 UTC
-
PET-CT scans could sharpen radiation targeting for liver tumors
Knowledge-focused CompletedThis study investigates whether PET-CT scans can accurately measure the radiation dose delivered by radioactive spheres during a liver cancer treatment called radioembolization. Researchers will compare scans taken before and after the procedure in patients with liver tumors. The…
Sponsor: Fox Chase Cancer Center • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC